Design strategies for long-acting anti-HIV pharmaceuticals.

[1]  Mardge H. Cohen,et al.  Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy , 2020, BMC Women's Health.

[2]  V. Soriano,et al.  Long-acting antiretroviral therapy , 2020, Nature Materials.

[3]  J. R. Somoza,et al.  Clinical targeting of HIV capsid protein with a long-acting small molecule , 2020, Nature.

[4]  N. Galai,et al.  “A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania , 2020, PloS one.

[5]  Anil B. Jindal,et al.  Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. , 2020, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Jon Cohen.  Long-acting drug acts like a short-term AIDS vaccine. , 2020, Science.

[7]  T. Heine,et al.  Making 2D topological polymers a reality , 2020, Nature Materials.

[8]  J. Meza,et al.  A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug , 2020, Nature Materials.

[9]  M. Tolstrup,et al.  The Potential of Long-Acting, Tissue-Targeted Synthetic Nanotherapy for Delivery of Antiviral Therapy Against HIV Infection , 2020, Viruses.

[10]  P. Cahn,et al.  Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. , 2020, The New England journal of medicine.

[11]  S. Oka,et al.  Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. , 2020, The New England journal of medicine.

[12]  H. Gendelman,et al.  Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues , 2020, Theranostics.

[13]  C. Flexner,et al.  Long-acting implants to treat and prevent HIV infection. , 2019, Current opinion in HIV and AIDS.

[14]  E. De Clercq,et al.  Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2019, European journal of medicinal chemistry.

[15]  E. De Clercq,et al.  Ligand-based design of nondimethylphenyl-diarylpyrimidines with improved metabolic stability, safety and oral pharmacokinetic profiles. , 2019, Journal of medicinal chemistry.

[16]  J. Mascola,et al.  Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. , 2019, The lancet. HIV.

[17]  Allan C. deCamp,et al.  Safety, pharmacokinetics, and immunogenicity of the combination of the broadly neutralizing anti-HIV-1 antibodies 3BNC117 and 10-1074 in healthy adults: A randomized, phase 1 study , 2019, PloS one.

[18]  M. Peet,et al.  Topical Inserts: A Versatile Delivery Form for HIV Prevention , 2019, Pharmaceutics.

[19]  E. De Clercq,et al.  Follow on-based optimization of the biphenyl-DAPYs as HIV-1 nonnucleoside reverse transcriptase inhibitors against the wild-type and mutant strains. , 2019, Bioorganic chemistry.

[20]  A. van der Straten,et al.  Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP) , 2019, Pharmaceutics.

[21]  S. Sarafianos,et al.  Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase , 2019, Pharmaceuticals.

[22]  Tom O. McDonald,et al.  Tuning HIV drug release from a nanogel-based in situ forming implant by changing nanogel size. , 2019, Journal of materials chemistry. B.

[23]  C. Flexner.  Modern Human Immunodeficiency Virus Therapy: Progress and Prospects , 2018, Clinical pharmacology and therapeutics.

[24]  H. Gundacker,et al.  Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  J. Baeten,et al.  Topical delivery of long-acting antiretrovirals to prevent HIV acquisition. , 2019, Current opinion in HIV and AIDS.

[26]  R. Mumper,et al.  Ultra-long-acting removable drug delivery system for HIV treatment and prevention , 2018, Nature Communications.

[27]  Nico Pfeifer,et al.  Safety and anti-viral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals , 2018, Nature Medicine.

[28]  Marian E. Gindy,et al.  Extended-Duration MK-8591-Eluting Implant as a Candidate for HIV Treatment and Prevention , 2018, Antimicrobial Agents and Chemotherapy.

[29]  C. Flexner.  Antiretroviral implants for treatment and prevention of HIV infection , 2018, Current opinion in HIV and AIDS.

[30]  S. Sarafianos,et al.  4′-Ethynyl-2-fluoro-2′-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor , 2018, Current opinion in HIV and AIDS.

[31]  Yoshiaki Nishimura,et al.  A single injection of crystallizable fragment domain–modified antibodies elicits durable protection from SHIV infection , 2018, Nature Medicine.

[32]  R. Koup,et al.  New-Generation High-Potency and Designer Antibodies: Role in HIV-1 Treatment. , 2018, Annual review of medicine.

[33]  M. Ramgopal,et al.  Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment. , 2018, AIDS research and human retroviruses.

[34]  J. Mascola,et al.  Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults , 2018, PLoS medicine.

[35]  J. Mascola,et al.  Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial , 2017, PLoS medicine.

[36]  S. Lewin,et al.  HIV-hepatitis B virus coinfection: epidemiology, pathogenesis, and treatment , 2017, AIDS.

[37]  D. Chiappetta,et al.  Advances in therapy for the prevention of HIV transmission from mother to child , 2017, Expert opinion on pharmacotherapy.

[38]  G. di Perri,et al.  Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. , 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[39]  Ben Murrell,et al.  Antibody 10-1074 suppresses viremia in HIV-1-infected individuals , 2017, Nature Medicine.

[40]  S. Kapiga,et al.  Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. , 2016, The New England journal of medicine.

[41]  M. Marzinke,et al.  Pharmacodynamic correlations using fresh and cryopreserved tissue following use of vaginal rings containing dapivirine and/or maraviroc in a randomized, placebo controlled trial , 2016, Medicine.

[42]  Erica B. Schlesinger,et al.  A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis , 2016, Pharmaceutical Research.

[43]  A. Ray,et al.  Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. , 2016, Antiviral research.

[44]  J. Mascola,et al.  Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection , 2015, Science Translational Medicine.

[45]  Andrew Owen,et al.  Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Daniel A. Solomon,et al.  Current state and limitations of daily oral therapy for treatment , 2015, Current opinion in HIV and AIDS.

[47]  Thomas J. Smith,et al.  Pharmacokinetics of Long-Acting Tenofovir Alafenamide (GS-7340) Subdermal Implant for HIV Prophylaxis , 2015, Antimicrobial Agents and Chemotherapy.

[48]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[49]  D. Hazuda,et al.  Derivatives of Mesoxalic Acid Block Translocation of HIV-1 Reverse Transcriptase* , 2014, The Journal of Biological Chemistry.

[50]  U. Bredeek,et al.  Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults , 2013, Journal of acquired immune deficiency syndromes.

[51]  H. Gendelman,et al.  Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy , 2013, Antimicrobial Agents and Chemotherapy.